Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Systematic assessment of omega-3 fats on cardiovascular health suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supplement trials) putting into question previous suggestions of benefits from EPA and DHA supplements. Low-quality evidence suggests ALA may slightly reduce CVD event risk, CHD mortality and arrhythmia. Additional large studies of omega 3 are currently underway.
Related stories
- Saving the PASS system for the sake of England’s FH Services, for current and future generations
- The national Child Parent Screening Service (CPSS) pilot has been extended until October 2024
- Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
- how the NHS is working to deliver improved lipid management
- HEART UK 36th Annual Medical and Scientific Conference 2023 LIPIDS – THE BEST YET - CONFERENCE REVIEW
- Our new Lipidology Podcast
- Recently formed Lipoprotein(a) Taskforce publishes Call to Action to increase recognition and acceptance of Lp(a) as an ASCVD risk factor
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023